SCHEDULE: Capital International Investors Discloses 1.2% Stake in CRISPR Therapeutics
Beneficial Ownership Report
Capital International Investors has filed an amended Schedule 13G, reporting a passive 1.2% beneficial ownership stake in CRISPR Therapeutics AG.
Summary
- Capital International Investors (CII) filed an Amendment No. 4 to Schedule 13G regarding its ownership in CRISPR Therapeutics AG.
- CII beneficially owns 1,186,794 shares of CRISPR Therapeutics AG Common Stock.
- This ownership represents 1.2% of the outstanding shares, based on 95,300,233 shares believed to be outstanding.
- CII holds sole voting power and sole dispositive power over all 1,186,794 shares.
- The filing certifies that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing. It is a standard disclosure of a passive ownership stake by an institutional investor, providing no new information regarding company performance or strategic direction.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that Schedule 13G filings are routine disclosures by institutional investors holding less than 5% of a company's stock with a passive investment intent. This filing indicates Capital International Investors' continued or adjusted passive interest in CRISPR Therapeutics AG, a prominent player in the biotechnology and gene-editing sector.
Stakeholder Impact
- Shareholders: Provides transparency regarding institutional ownership, confirming a significant, albeit passive, stake by Capital International Investors.
Key Dates
| Date | Description |
|---|---|
| 01/30/2026 | Date of event which requires filing of this statement |
| 02/05/2026 | Signature date of the filing |
Recommendation
holdThis Schedule 13G filing is a routine disclosure of a passive ownership stake by an institutional investor. It does not provide new fundamental information about CRISPR Therapeutics AG's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. Investors should 'hold' and look to other filings for operational insights.
Keywords
CRISPR Therapeutics AG, CRSP, Capital International Investors, Schedule 13G, Beneficial Ownership, Investment Adviser, Common Stock, Biotechnology, Gene Editing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.